BridgeMD
New treatment option for Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Official title Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
ClinicalTrials.gov ID: NCT06838208
What this study is testing
What is Tislelizumab, Carboplatin /Cisplatin, Etoposide?
Tislelizumab, Carboplatin /Cisplatin, Etoposide is an investigational medicine, being studied as a potential treatment for extensive-stage small cell lung cancer (es-sclc).
Also referred to as radiotherapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age≥18 years old, male or female, signed Informed Consent Form (ICF);
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Histologically or cytologically confirmed ES-SCLC;
- No prior systemic treatment for ES-SCLC;
- At least one measurable (RECIST 1.1) chest lesion capable of 15Gy/5f irradiation;
You likely can't join if
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis;
- Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1)...
- Was administered a live vaccine ≤ 4 weeks before treatment;
- Active autoimmune diseases or history of autoimmune diseases that may relapse;
- Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment;
- With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;
See the full eligibility criteria
- Age≥18 years old, male or female, signed Informed Consent Form (ICF);
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Histologically or cytologically confirmed ES-SCLC;
- No prior systemic treatment for ES-SCLC;
- At least one measurable (RECIST 1.1) chest lesion capable of 15Gy/5f irradiation;
- Adequate hematologic and end organ function;
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis;
- Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti...
- Was administered a live vaccine ≤ 4 weeks before treatment;
- Active autoimmune diseases or history of autoimmune diseases that may relapse;
- Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment;
- With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;
- Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to treatment, including but not limited to tuberculosis infection;
- Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to starting treatment;
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.